15 results about "Cerebral Spinal Fluid" patented technology

Ventricular catheters and their methods of use are disclosed. In some embodiments, the disclosed ventricular catheters may reduce, or substantially prevent, obstruction of the catheter by astrocytes or other brain tissue due to adhesion and / or growth within the catheter. For example, in some embodiments, the holes and internal lumen of a ventricular catheter may be constructed such that the wall shear stresses applied within the holes and internal lumen of the catheter are greater than a threshold shear stress to prevent cell adhesion and growth within the catheter.

The present disclosure relates to a method of reducing urine glycosaminoglycans (GAG) or cerebral spinal fluid (CSF) glycosaminoglycans (GAG) in a subject, comprising: administering a single dose of a population of modified B cells to the subject.

The invention discloses a cerebrospinal fluid drainage control device with a sensor. The cerebrospinal fluid drainage control device comprises an intracranial pressure monitoring system, a signal processing system and a drainage bag lifting system. The intracranial pressure monitoring system comprises an intracranial pressure sensor and a body position sensor which are arranged in the cranial cavity and the head of a patient respectively. The signal processing system comprises a central processing unit and a signal conversion module and is connected with the sensor through a data line. The drainage bag lifting system comprises a lifting support and a driving unit, and automatic adjustment of the height of the drainage bag is achieved. According to the device, automatic adjustment of drainage pressure is achieved through real-time monitoring and intelligent processing.

The present disclosure provides systems and methods for clinical decision support of the diagnosis of infection. In an aspect, a system or method of clinical decision support (CDS) may comprise CDS of metagenomic next-generation sequencing results of clinical samples, (e.g., cerebral spinal fluid) to evaluate sample quality and microbial composition to diagnose a microbial infection (e.g., of the central nervous system).

Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and / or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.

A cerebral spinal fluid shunt plug includes a shunt plug housing having a shunt valve recess formed therein and a window recess with an access hole. The cerebral spinal fluid shunt plug also includes a shunt valve shaped and dimensioned for positioning within the shunt valve recess of the shunt plug housing and a lucent disk shaped and dimensioned for the passage through the central access hole of the shunt plug housing. In another embodiment, a cerebral spinal fluid shunt plug includes a shunt plug housing having a shunt valve recess formed therein and an intracranial monitoring device recess with an access hole. A shunt valve is positioned within the shunt valve recess of the shunt plug housing and an intracranial monitoring device is passed through the central access hole of the shunt plug housing.

The present disclosure provides systems and methods for detection of microbial DNA and RNA. In an aspect, a system or method for detection of microbial DNA or RNA comprises metagenomic next-generation sequencing of clinical samples (e.g., cerebral spinal fluid) to detect the microbial composition of the sample to diagnose a microbial infection (e.g., of the central nervous system).

Various examples are provided for disposable medical sensors that can be used for the detection of cerebral spinal fluid. In one example, a medical sensing system includes a disposable sensing unit comprising a functionalized sensing area disposed between electrodes; and a portable sensing unit analyzer including pulse generation circuitry that can generate synchronized gate and drain pulses and a transistor with a gate electrically coupled to one electrode. A gate pulse output of the pulse generation circuitry is electrically coupled to a second electrode and a drain pulse output is electrically coupled to a drain of the transistor. In another example, a method includes providing a sample to a functionalized sensing area, generating synchronized gate and drain pulses for a transistor, the gate pulse provided via the electrodes and functionalized sensing area, and sensing an output of the transistor that is a function of a target concentration of the sample.

Disclosed is a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into a neurological injury or disease site, the composition comprising: (a) a gel forming molecule; and (b) a chemokine receptor type 5 (CCR5) antagonist. Also disclosed is a method of treating a neurological injury or disease of a subject, comprising (a) mixing NPCs with the composition as disclosed herein; and (b) administering a mixture of the NPCs and the composition into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Also disclosed is use of a mixture of NPCs and the composition as disclosed herein in the manufacture of a medicament for treating a neurological injury or disease of a subject, wherein the mixture is to be administered into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Further disclosed is a kit for use in supporting survival and differentiation of NPCs grafted into a neurological injury or disease site, the kit comprising: (a) the composition as disclosed herein; (b) artificial cerebral spinal fluid (a-CSF); (c) CaCl2; and (d) thrombin.

The invention relates to methods for monitoring the implementation of physical rehabilitation therapy in the case of diseases related to impaired blood circulation and cerebrospinal fluid circulation in the brain, as well as in the case of myotonic syndrome. Prior to commencement of physical rehabilitation therapy, data about the patient's continuous electrical potentials in five zones, frontal (Fz), central / parietal (Cz), occipital (Oz), right (Td) and left (Ts), are obtained by neural energy mapping. The obtained readings are compared with a norm, determining any deviation from the norm (mV). Physical rehabilitation therapy is implemented with neural energy mapping being carried out in real time. The therapy implemented is adjusted if the readings obtained deviate from the norm. The method makes it possible to monitor the implementation of physical rehabilitation therapy in the case of diseases related to impaired blood circulation and cerebrospinal fluid circulation in the brain, as well as in the case of myotonic syndrome.

The present disclosure relates to a method of reducing urine glycosaminoglycans (GAG) or cerebral spinal fluid (CSF) glycosaminoglycans (GAG) in a subject, comprising: administering a single dose of a population of modified B cells to the subject.

Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam (b); an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam (b); a detector operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and / or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.

A method and apparatus for preventing brain death by using rapid and safe cooling of the brain is disclosed. The fourth ventricle is accessed through the patient's neck by using a specially designed needle / cannula that enters the cistema magna with an entry through the patient's neck, allowing the cooled artificial cerebral spinal fluid (aCSF) to flow around the brain. The aCSF exits from an opening in the skull where temperature / pressure sensors are placed. Data is sent to a computer controlled motorized system that pumps the cooled aCSF to the needle / cannula placed in the cistema magna. The pumping of the aCSF is controlled to maintain a predetermined temperature and / or pressure of the outlet aCSF.

The application belongs to the technical field of electrophysiological recording, and discloses a preparation method of brain slices of middle-aged and old mice for electrophysiological recording and application, wherein a modified artificial cerebral spinal fluid (ACSF) for brain slices of old mice is introduced in the preparation process of brain slices of middle-aged and old mice, which comprises: an artificial cerebral spinal fluid (section ACSF, sACSF) used when the brain slices of middle-aged and old mice are prepared, and an artificial cerebral spinal fluid (culture ACSF, cACSF) used when the brain slices of middle-aged and old mice are incubated for electrophysiological recording. In the method, the activity of the brain slices of middle-aged and old mice is significantly improved and the duration of the activity is prolonged by the use of the two ACSFs, high-quality brain slice samples of middle-aged and old mice are provided for the research on neurodegenerative diseases such as aging, Alzheimer's disease and Parkinson's syndrome, and the method has a wide application prospect in scientific research.

Disclosed are methods for determining blood brain barrier disruption in a subject in need thereof. The methods include administering intravascularly a contrast agent to the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in brain parenchyma and / or cerebral spinal fluid within the region of interest.